Supplemental Figure 1 · 23 45 6 7 8 Supplemental Figure 3 HNSC (num(T)=519;num(N)=44) 0 50 100 150...
Transcript of Supplemental Figure 1 · 23 45 6 7 8 Supplemental Figure 3 HNSC (num(T)=519;num(N)=44) 0 50 100 150...
0.23
0.35
TIGIT-APC
LAG
-3-B
V42
1
TIGIT-APC
TIM
-3-P
E
Supplemental Figure 1
3.36
0.93
Spleen(WT) Spleen(Con) TIL(Con)
Gated on CD8+A
B
TIGIT-APC
LAG
-3-B
V42
1
TIGIT-APC
TIM
-3-P
E
4.57
Spleen(WT) Spleen(Con) TIL(Con)
Gated on CD4+
2.34
0.99
6.63
0.80 4.09
1.89 2.53
Supplemental Figure 2
B
Pre-sorting
Post-sorting
CD3-FITC
CD
8-P
erC
P-C
y5.5
8.4877.5799.1457.46
A
Pre-sorting
Post-sorting
FSC-A
SS
C-A
CD4-FITC
SS
C-A
FSC-A
FS
C-W
93.70 96.90 26.70 14.88
CD25-PE
Fox
p3-
Per
CP
-Cy5
.5
FSC-H
FS
C-W
99.53
FSC-A
SS
C-A
CD4-FITCS
SC
-AFSC-A
FS
C-W
93.06 96.93 93.95 95.56
CD25-PE
Fox
p3-
Per
CP
-Cy5
.5
FSC-H
FS
C-W
98.62
FSC-A
SS
C-A
FSC-A
FS
C-W
FSC-H
FS
C-W
CD3-FITC
CD
8-P
erC
P-C
y5.5
FSC-A
SS
C-A
FSC-A
FS
C-W
FSC-H
FS
C-W
99.00100.0099.7181.57
Supplemental Figure 3
23
45
67
82
34
56
78
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
*
HNSC(num(T)=519; num(N)=44)
0 50 100 150 200
0.0
0.2
0.4
0.6
0.8
1.0
Overall Survival
MonthsP
erc
en
t su
rviv
al
Low PVR TPMHigh PVR TPM
Logrank p=0.0023 HR(high)=1.5
p(HR)=0.0025 n(high)=259
n(low)=259
BA
Supplemental Figure 4
HE HE CD155 CD155
HE HE CD155 CD155
HE HE CD155 CD155 50 m
A
B Cn=35
LNHNSCC
300
200
100
0
300
200
100
0
T1 + T2 T3 + T4
P = 0.9148 n=67
n=145P = 0.1122
CD155-APC
SS
C-A
Supplemental Figure 6
FVD-eFlour506
SS
C-A
FSC-A
SS
C-A
FSC-A
FS
C-W
CD11b-FITC
SS
C-A
A
BCD155-APC
SS
C-A
FMO-CD155
FMO-CD155
CD155
CD155
Pre-sorting Post-sorting
91.3920.40
CD11b-FITC
SS
C-A
CD11b-FITC
SS
C-A
Ly6G-PE
Ly6C
-P
E-C
y7
7.61
78.9891.01
99.40
98.83
PMN-MDCS
M-MDSC
Ly6G-PE
Ly6C
-P
E-C
y7
Ly6G-PE
Ly6C
-P
E-C
y7
Supplemental Figure 7
A
ISO
Ant
i-TIG
IT
Liver Kidney
100μm
0
Gr-
1+(%
) on
CD
11b+
cells
B
20
40
60ISO
Anti-TIGIT
P = 0.2295
P = 0.3945
Spleen Tumor
Fox
p3-
Per
CP
-Cy5
.5
Supplemental Figure 8
3.64
6.39 0.05
0.26
14.45
9.18
27.35
1.12
0.18
0.11
CD4-FITC
SS
C-A
CD8-PerCP-Cy5.5
SS
C-A
CD11b-FITC
Gr1
-AP
C
CD25-PE
Gated on CD4+
Isotype Anti-CD4
Isotype Anti-CD8
A B
C
Isotype Anti-Gr1
Isotype Anti-CD25
Blood
LN
D
0
TIG
IT+(%
) on
CD
8+ce
lls
20
40
60
ISO
Anti-PD1
P = 0.4565
P = 0. 2700
Spleen Tumor